Crossmark

p53 activation enhances the sensitivity of non-small cell lung cancer to the combination of SH003 and docetaxel by inhibiting de novo pyrimidine synthesis

Crossref DOI link: https://doi.org/10.1186/s12935-024-03337-x

Published Online: 2024-05-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Choi, Yu-Jeong

Lee, Kangwook

Lee, Seo Yeon

Kwon, Youngbin

Woo, Jaehyuk

Jeon, Chan-Yong

Ko, Seong-Gyu
Funding

Funding for this research was provided by:

Ministry of Science and ICT, South Korea (2020R1A5A2019413)
License Information

Text and Data Mining valid from 2024-05-04

Version of Record valid from 2024-05-04
More Information

Article History

Received: 8 June 2023

Accepted: 18 April 2024

First Online: 4 May 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below